Breakthrough drug nearly doubles survival with advanced pancreatic cancer – an oncologist explains how daraxonrasib overcame an ‘undruggable’ disease
Daraxonrasib nearly doubled overall survival from 6.7 months to 13.2 months after diagnosis.
Daraxonrasib, a KRAS‑targeting agent, was shown in a Phase 3 trial to nearly double overall survival in patients with metastatic pancreatic cancer (median OS 13.2 months vs 6.7 months) and to reduce the risk of death by 60 %. The most frequent adverse event was a skin rash affecting > 86 % of patients. The drug is administered orally once daily and operates by binding cyclophilin A to inhibit KRAS activity.
A 60 % reduction in the risk of death for patients with metastatic pancreatic cancer, a disease with a historically very short survival, represents a significant therapeutic breakthrough.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.